MAGEA3 and plasma cell myeloma: Further, lethal off-target recognition mediated by engineered TCRs has been reported in two patients with metastatic melanoma and multiple myeloma treated with an affinity-enhanced TCR generated for adoptive therapy against the HLA-A*01-restricted MAGE-A3 peptide EVDPIGHLY (13, 15).